Contractor profile

Regeneron Pharmaceuticals Inc

FY2026 ended Sep 30 · data still posting · data as of 2026-11-01†

† DoD contract data posts to USAspending about 90 days after award.

prime recipient of federal awards · UEI N3F9MH7E6HD6 Source
$279.4M
Obligated
FY2026 · data still posting
2
Funding agencies
100%
From Health and Hum…
0%
Non-competed
1
States
100%
In New York
2
Industries

In FY2026, Regeneron Pharmaceuticals Inc received $279.4M in federal awards from 2 agencies, 100% of it from the Department of Health and Human Services, with 100% of the work performed in New York. Across FY2020 to FY2026 its recorded total is $6.8B. FY2026 ended Sep 30 and its data is still posting. Computed

Where this money comes from

Source
FUNDING AGENCIES
REGENERON PHARMACEUTICAL
HHS
$0.3B
Regeneron Pharmaceuticals Inc
$0.3B
FY2026 obligated
band width = obligations · FY2026 · source: USASpending.gov

Where the work lands

Source
New York$279.4M

Key takeaways

Computed
FY2026 ended Sep 30 · data still posting · data as of 2026-11-01
  • Regeneron Pharmaceuticals Inc received $279.4M in federal obligations in FY2026 (data still posting).
  • The Department of Health and Human Services accounted for 100% of it.
  • Its largest recorded industry was Research and Development in Biotechnology, at $279.4M.
  • New York was its largest place of performance, with 100% of the work.

Obligations by year

Computed
$638.4M
FY20
$5.6B
FY21
$326.5M
FY23
$279.4M
FY26 partial
▼ 49%
FY20 to FY23

Awards

Source

Largest active awards by total value

Awards whose period of performance overlaps FY2026, by the amount obligated on each so far.

AwardIDAgencyObligatedStartEndPlace
Contract HHSO100201700016CHHSO100201700016CDepartment of Health and Human Services$973.6M2017-09-302031-09-29New York
Regeneron Other Transaction Authority (OTA) AwardHHSO100201700020CDepartment of Health and Human Services$278.8M2017-09-212027-09-25New York

Largest FY2026 awards

Awards that started in FY2026, by the amount obligated on each so far.

No award on record started in FY2026.

What it does (NAICS / PSC)

Research and Development in Biotechnology$279.4M

Competition

0%non-competed (often called no-bid), of $279.4M in contract obligations in FY2026Computed

This describes how contracts were awarded, not wrongdoing.

Similar federal contractors

Computed
Alliance for Energy Innovation, LLC$1B
University of Alabama at Birmingham$318K
Merck Sharp & Dohme LLC$0
Glaxosmithkline, LLC$0
University of North Carolina at Chapel Hill$0
Arizona State University$0
Seattle Children's Hospital−$55
The University of Texas Health Science Center at San Antonio−$2.3K

Corporate family

Single registration: no combined family.

Political contributions

Regeneron Pharmaceuticals, Inc. PACInferredgave$280.5Kto members of CongressSource
Paul Tonko (Democrat)$25K
Thom Tillis (Republican)$17K
Mike Crapo (Republican)$12K
Chuck Grassley (Republican)$11.5K
Pete Aguilar (Democrat)$10K
Steve Daines (Republican)$10K
Richard E. Neal (Democrat)$10K
Charles E. Schumer (Democrat)$10K
Yvette D. Clarke (Democrat)$9K
Tim Scott (Republican)$8.5K

linked through public filings, not a claim of coordination. contribution reported to the FEC, a public campaign-finance record.

Related

Why the labels? The graph is only worth anything if the links are trusted. Facts taken straight from a federal filing are Source; figures we calculate are Computed; links we infer (corporate parents, districts, similar contractors, connections between records) are Inferred, worded carefully, never asserted as fact and never a claim that one thing caused another. Spot an error? Tell us.